Stockpolly
Search
Delisting risk
CODX · NASDAQ · Biotechnology

Co-Diagnostics (CODX)

Develops portable PCR instruments, test cups, and molecular assays.

$1.11
Pre-market−0.04 (−3.90%)
At close$1.16(−2.94%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue240310000000
Cost of revenue030000000000
Gross profit210200000000
111210101112987896
Research & development666655554564
564457332232
Selling & marketing222111111100
General & administrative343346332232
Other expenses000000000000
Operating income−9−12−10−8−10−12−9−8−7−8−9−6
111011100−1900
Interest income000000000000
Other non-operating income0−1−10−1−1−1001900
Income before tax−8−11−9−8−10−11−8−8−7−26−9−6
Income tax expense−24000000−1000
Net income from continuing operations−6−15−9−8−10−11−8−8−6−26−9−6
Net income−6−15−9−8−10−11−8−8−6−26−9−6
EPS, basic−$6.11−$14.10−$9.36−$7.57−$9.54−$10.01−$7.05−$7.00−$4.66−$16.54−$4.06−$1.46
EPS, diluted−$6.11−$14.10−$9.36−$7.57−$9.54−$10.01−$7.05−$7.00−$4.66−$16.54−$4.06−$1.46
Weighted average shares, basic111111111124
Weighted average shares, diluted111111111124
EBITDA−9−11−9−7−9−11−7−7−7−26−9−6
Depreciation & amortization000000000000
EBIT−9−11−9−8−10−11−8−8−7−26−9−6